Introduction Alector is at the forefront of developing innovative therapeutics for Alzheimer's disease, dementia, and other neurodegenerative disorders by utilizing advanced antibody technology and groundbreaking discoveries in neuroimmunology and human genetics. The company's strategy involves generating and validating unique antibody drugs that target crucial disease-altering pathways. Alector has formed a strategic partnership with Adimab, a leader in antibody discovery and optimization, to facilitate this process. |
Disease Domain | Count |
---|---|
Nervous System Diseases | 3 |
Neoplasms | 2 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 4 |
Unknown | 1 |
Target |
Mechanism SORT1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PGRN modulators [+1] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TREM2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Oct 2024 |
Sponsor / Collaborator |
Start Date08 Dec 2023 |
Sponsor / Collaborator |
Start Date20 Oct 2023 |
Sponsor / Collaborator GSK Plc [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Latozinemab ( SORT1 ) | Frontotemporal Dementia More | Phase 3 |
AL-002 ( TREM2 ) | Alzheimer Disease More | Phase 2 |
AL-101(Alector) ( PGRN x SORT1 ) | Alzheimer Disease More | Phase 2 |
ADP-022 ( Chk ) | Neoplasms More | Preclinical |
AL-009 ( Siglec ) | Solid tumor More | Discovery |